SEARCH

SEARCH BY CITATION

References

  • 1
    Withrow SJ, Vail DM and Page R. Small Animal Clinical Oncology. 5th edn., St. Louis, Elsevier Saunders, 2013.
  • 2
    Andrade RS, Heron DE, Degirmenci B, Filho PAA, Branstetter BF, Seethala RR, Ferris RL and Avril N. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. International Journal of Radiation Oncology, Biology, and Physics 2006; 65: 13151322.
  • 3
    Menda Y and Graham MM. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Seminars in Nuclear Medicine 2005; 35: 214219.
  • 4
    Bar-Shalom R, Valdivia AY and Blaufox MD. PET imaging in oncology. Seminars in Nuclear Medicine 2010; 30: 150185.
  • 5
    Nestle U, Weber W, Hentschel M and Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Physics in Medicine and Biology 2009; 54: R1R25.
  • 6
    Chen K and Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Seminars in Oncology 2011; 38: 7086.
  • 7
    Zhu A, Lee D and Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Seminars in Oncology 2011; 38: 5569.
  • 8
    Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carninon R, Colombini E, Valentini MC, Giovanella L, Spriano G and Gandolfo S. Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head & Neck 2008; 30: 14881496.
  • 9
    Ng SH, Yen TC, Liao CT, Chang JTC, Chan SC, Ko SF, Wang HM and Wong HF. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. Journal of Nuclear Medicine 2005; 46: 11361143.
  • 10
    Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H and Gregoire V. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233: 93100.
  • 11
    Xu GZ, Zhu XD and Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head & Neck 2011; 33: 8794.
  • 12
    Liao CT, Wang HM, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, Ng SH, Hsueh C, Lee LY, Lin CH and Yen TC. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. Journal of Nuclear Medicine 2011; 52: 180187.
  • 13
    LeBlanc AK, Wall JS, Morandi FM, Kennel SJ, Stuckey A, Jakoby B, Townsend DW and Daniel GB. Normal thoracic and abdominal distribution of 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) in adult cats. Veterinary Radiology & Ultrasound 2009; 50: 436441.
  • 14
    Yoshikawa H, Randall E, Kraft S and LaRue S. Comparison between 18F-fluoro-2-deoxy-d-glucose positron emission tomography and contrast-enhanced computed tomography for measuring gross tumor volume in cats with oral squamous cell carcinoma. Veterinary Radiology & Ultrasound 2013; 54: 307313.
  • 15
    Gendler A, Lewis JR, Reetz JA and Schwarz T. Computed tomographic features of oral squamous cell carcinoma in cats: 18 cases (2002–2008). Journal of the American Veterinary Medical Association 2010; 236: 319325.
  • 16
    Cherry SR. The 2006 Henry N. Wagner Lecture: of mice and men (and positrons)—advances in PET imaging technology. Journal of Nuclear Medicine 2006; 47: 17351745.
  • 17
    Oehr P, Biersack HJ and Coleman RE. PET and PET-CT on Oncology. Berlin, Springer, 2004.
  • 18
    Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, Murakami D, Tomiguchi S, Oya N, Katsuragawa S and Yamashita Y. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics 2007; 68: 377382.
  • 19
    Beyer T, Townsend DW, Czernin J and Freudenberg LS. The future of hybrid imaging—part 2: PET/CT. Insights Imaging 2011; 2: 225234.
  • 20
    Mawlawi O and Townsend DW. Multimodality imaging: an update on PET/CT technology. European Journal of Nuclear Medicine and Molecular Imaging 2009; 36(suppl 1): S15S29.
  • 21
    Ogilvie GK and Moore AS. Feline Oncology. Trenton, NJ, Veterinary Learning Systems, 2001: 191219.
  • 22
    Nguyen HC, Kaushik A, Wolverson MK and Osman MM. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncologica 2011; 50: 670677.
  • 23
    Greven KM. Positron-emission tomography for head and neck cancer. Seminars in Radiation Oncology 2004; 14: 121129.
  • 24
    Schoder H and Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Seminars in Nuclear Medicine 2004; 34: 180197.
  • 25
    Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, LeBlanc M, Krohn K, Eary J and Laramore GE. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head & Neck 2005; 27: 478487.
  • 26
    Delbeke D, Coleman E, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Hubner K, Stabin MG, Zubal G, Kachelriess M, Cronin V and Holbrook S. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. Journal of Nuclear Medicine 2006; 47: 885895.
  • 27
    Hara T, Higashi T, Nakamoto Y, Suga T, Saga T, Ishimori T, Ishizu K, Kawashima H, Kawase S, Matsumoto K and Togashi K. Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging? Annals of Nuclear Medicine 2009; 23: 657669.
  • 28
    Mirpour S, Meteesatien P and Khandani AH. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT? Revista Española de Medicina Nuclear e Imagen Molecular 2012; 31: 7177.